The ROS1 inhibitor market for NSCLC, valued at around $290 million in 2023 across the USA, Europe, and Japan, is set for growth with new-generation therapies targeting resistance mutations.

On Friday, Nuvalent Inc (NUVL) stock saw a modest uptick, ending the day at $89.22 which represents a slight increase of $0.73 or 0.82% from the prior close of $88.49. The stock opened at $89 and ...

The metastatic non-small cell lung cancer (mNSCLC) treatment landscape has vastly expanded over the past two decades as a ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Fintel reports that on October 24, 2024, UBS initiated coverage of Nuvalent (NasdaqGS:NUVL) with a Neutral recommendation.

On Thursday, UBS initiated coverage on Nuvalent (NASDAQ:NUVL) stock with a Neutral rating and established a price target of $100.00. The firm's analysis suggests that Nuvalent, which is focused on ...

UBS initiated coverage of Nuvalent (NUVL) with a Neutral rating and $100 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases.